View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, June 11 (HealthDay News) -- For patients with dysglycemia and at high risk of cardiovascular events, supplementation with omega 3 (n-3) fatty acids does not reduce the rate of cardiovascular events, according to a study published online June 11 in the New England Journal of Medicine to coincide with presentation at the American Diabetes Association's 72nd Scientific Sessions, held from June 8 to 12 in Philadelphia.
Jackie Bosch, from McMaster University and Hamilton Health Sciences in Canada, and colleagues from the Outcome Reduction with Initial Glargine Intervention trial, randomized 12,536 adults (mean age, 63.5 years) with cardiovascular risk factors and impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to a 1-gram capsule containing at least 900 mg n-3 fatty acids or placebo, in addition to either insulin glargine or standard care.
During a median of 6.2 years of follow-up, the researchers found that the incidence of death from cardiovascular causes was not significantly different for those receiving n-3 fatty acids or standard care (9.1 versus 9.3 percent; P = 0.72). Supplementation with n-3 fatty acids had no significant effect on the rates of major vascular events, death from any cause, or death from arrhythmia. Among patients receiving n-3 fatty acids, triglyceride levels were reduced by 14.5 mg/dL more than among those receiving placebo (P < 0.001), with no significant impact on other lipids. The rates of adverse effects were similar between the groups.
"Daily supplementation with 1 gram of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events," the authors write.
The study was supported by Sanofi and study drugs were provided by Pronova BioPharma Norge; several authors disclosed financial ties to pharmaceutical companies, including Sanofi.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top